Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Omeros is a clinical-stage biopharmaceutical company focused on inflammation, bleeding, and central nervous system disorders. Its primary platform, PharmacoSurgery, delivers low-dose therapeutic combinations directly to surgical sites to preemptively inhibit inflammation. The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Grant Revenue | $2.1 million | $1.4 million |
| Research & Development Expenses | $23.5 million | $16.9 million |
| General & Administrative Expenses | $8.7 million | $5.3 million |
| Net Loss | $(29.3) million | $(21.1) million |
| Cash, Cash Equivalents & Short-Term Investments | $42.0 million | $60.3 million |
| Total Notes Payable | $9.8 million | $12.8 million |
| Accumulated Deficit | $(147.6) million | $(118.3) million |
Material Changes vs. Prior Period
- Revenue Increase: Grant revenue increased 47% year-over-year, driven by funding from Vulcan Inc. and the Life Sciences Discovery Fund (LSDF) for the GPCR program, partially offset by decreased revenue from The Michael J. Fox Foundation.
- Expense Growth: R&D expenses rose 39% due to higher clinical trial costs for OMS103HP and OMS302, increased consulting fees, and higher employee expenses. G&A expenses increased 66% primarily due to costs associated with being a public company.
- Debt Restructuring: In October 2010, the company entered a $20.0 million debt facility with Oxford Finance Corporation, borrowing $10.0 million to repay its prior BlueCrest loan in full. This resulted in a $296,000 loss on extinguishment of debt.
- Strategic Funding: Received $20.0 million from Vulcan Inc. and a $5.0 million grant from LSDF for the GPCR program. Used these funds to acquire intellectual property assets from Patobios Limited for approximately $10.8 million CAD.
Guidance, Outlook, and Risks
Outlook and Milestones
- OMS103HP (Arthroscopy): Phase 3 enrollment for ACL reconstruction is complete. Data release is expected in Q1 2011. Phase 3 trials for meniscectomy are being prepared.
- OMS302 (Ophthalmology): Phase 2b enrollment is complete; data release expected in Q1 2011.
- Liquidity: Management believes existing cash and investments ($42.0 million) are sufficient to fund operations for at least the next 12 months.
Risks and Contingencies
- Regulatory Approval: No products are approved. Success depends on positive Phase 3 data for OMS103HP and subsequent FDA approval, which is not guaranteed.
- Capital Requirements: The company expects to incur increasing losses. Future funding may be required via equity or debt, potentially causing dilution or restrictive covenants.
- Legal Proceedings: A former CFO has filed a lawsuit alleging violations of the Federal False Claims Act and wrongful termination. The company is vigorously defending the claims, but the outcome is uncertain.
- Contractual Obligations: The Vulcan and LSDF agreements require the company to screen 75% of known orphan GPCRs within 19 months and commit resources to medicinal chemistry efforts, limiting operational flexibility.
Investor Verification Checklist
- Cash Runway: Verify if the $42.0 million cash balance is sufficient to fund the anticipated increase in R&D and commercialization costs if OMS103HP data is positive.
- Phase 3 Data: Monitor the Q1 2011 data release for the OMS103HP ACL reconstruction trial, which is the primary catalyst for future revenue.
- Debt Covenants: Review the Oxford Finance Corporation loan agreement for material adverse change (MAC) clauses and covenants that could restrict operations or trigger default.
- Legal Exposure: Assess the potential financial impact of the qui tam lawsuit filed by the former CFO regarding NIH grants.
- Revenue Recognition: Confirm the accounting treatment of the Vulcan and LSDF funding, specifically how deferred revenue is recognized against incurred expenses.